EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy



Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy



Anti-Cancer Drugs 18(7): 817-820



The aim of this study was to evaluate the activity and toxicity of capecitabine as third-line treatment in patients with advanced renal cell carcinoma for whom immunotherapy had failed. Twenty-one patients with metastatic clear renal cell carcinoma were enrolled. Capecitabine was administered orally twice daily at a dosage of 2500 mg/m(2) for 14 days, followed by 7 days of rest. The median number of administered cycles was five (1-13). One patient (4.8%) achieved a remission after eight treatment cycles. Stable disease was observed in nine patients (42.8%), whereas 11 progressed (52.4%). The estimated median time to progression was 3.6 months (confidence interval: 1.4 to 5.2). The estimated median overall survival was 7.2 months (confidence interval: 4.6 to 8.8). The regimen was well tolerated and no unexpected toxic effects were observed. Capecitabine as third-line treatment showed a favourable toxicity profile, but exhibited low activity in patients with advanced renal cell carcinoma after failing immunotherapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 015207574

Download citation: RISBibTeXText

PMID: 17581304

DOI: 10.1097/CAD.0b013e3280a02f17



Related references

Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. American Journal of Kidney Diseases 39(1): 48-54, 2002

A pilot clinical trial of gemcitabine and capecitabine chemotherapy for the treatment of advanced renal cell carcinoma failing immunotherapy. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 35(2): 277-279, 2008

Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. Anti-Cancer Drugs 14(10): 779-784, 2003

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma. Oncologist 19(9): 917-918, 2015

Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma. Cancer Chemotherapy & Pharmacology. 32(4): 329-331, 1993

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: A phase II trial. British Journal of Cancer 89(12): 2213-2218, 15 December, 2003

Capecitabine in the treatment of metastatic renal cell carcinoma. British Journal of Cancer 83(5): 583-587, 2000

A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. Clinical & Translational Oncology 12(7): 503-508, 2010

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet. Oncology 16(3): 293-300, 2015

Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma. International Journal of Urology 16(6): 576-579, 2009

Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer Journal From Scientific American 3 Suppl 1(): S92-S97, 1998

Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma. Cancer 122(15): 2350-2355, 2016

Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy. Medical Oncology 26 Suppl 1: 18-22, 2009

Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment. Cancer Metastasis Reviews 31 Suppl 1: S3-S9, 2012

Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma. PharmacoEconomics 31(1): 15-24, 2013